



## **NextPoint Therapeutics to Showcase Multimodal Oncology Pipeline Targeting B7-H7-Positive Patients at the Piper Sandler 36<sup>th</sup> Annual Healthcare Conference**

**Cambridge, MA** –November 25, 2024 – [NextPoint Therapeutics](#), a clinical-stage biotechnology company developing a new class of precision immuno-oncology and tumor-directed therapeutics targeting the novel B7-H7 axis, today announced that Ivan Cheung, chief executive officer, will present at the Piper Sandler 36<sup>th</sup> Annual Healthcare Conference on Wednesday, December 4 at 1:50pm ET.

NextPoint will provide an overview of its pipeline that fully harnesses the unique features of the B7-H7 axis, a novel checkpoint pathway independent of PD-L1 as well as an exceptional tumor target for use in T cell engagers and antibody drug conjugates. These efforts are further enhanced by a validated clinical biomarker strategy designed to deliver breakthrough treatments to a broad group of newly defined B7-H7 positive patients.

### **About NextPoint Therapeutics**

NextPoint is launching a new world of precision immuno-oncology and tumor-targeting therapeutics through its leading scientific work on the novel B7-H7/HLA2 axis. Our innovative approach integrates foundational science with a defined clinical biomarker to identify the right patient population for each B7-H7-directed therapy, so that we can deliver a new class of monotherapies for patients. Our team of proven drug developers is simultaneously advancing therapeutic approaches blocking the B7-H7 immune signaling pathway and utilizing the unique upregulation of B7-H7 in cancer as an anchor for tumor-targeting treatment modalities. To learn more, visit [nextpointtx.com](https://nextpointtx.com).

### **Investor Contact:**

Argot Partners

[nextpoint@ArgotPartners.com](mailto:nextpoint@ArgotPartners.com)